– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosing in First-in-Human Trial – CAMBRIDGE, Mass....

– KVD900 600 mg Provides >90% Inhibition of Plasma Kallikrein Within 30 Minutes of Dosing – – Single 600 mg Dose of KVD900 Provides Protection of HK Cleavage for at Least 10 Hours – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 25, 2019-- KalVista Pharmaceuticals, Inc....

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 1, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Brian Pereira has...

– KVD900 Phase 2 HAE Trial Data Expected in 2019 – – KVD824 Named as Next Oral Plasma Kallikrein Inhibitor to Enter Clinic – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 4, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...